New appointment

#Appointment #Drug discovery #Life sciences #New appointment

Drug discovery’s top-level movers and shakers

It’s been another busy month for senior appointments in the drug discovery sector. David Favre, Chief Development Officer, SpliceBio Dr Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry. He joins SpliceBio from Innoskel,… Read More

#News

New appointment
#Appointment #Drug discovery #Life sciences #New appointment

12 key industry appointments

A round-up of the top senior appointments in the drug discovery sector over the last month. Renos Savva, Head of Innovation, Discovery Park Savva’s previous experience includes co-founding Domainex, recognised by the Financial Times in 2018 as the ‘fastest-growing drug discovery contract research… Read More

#News

New appointments
#Appointment #Drug discovery #Life sciences #New appointment #Pharmaceutical industry

March’s key industry appointments

A round-up of the latest senior appointments in the drug discovery sector over the last month. Julian Collins, Jana Windt and Michiel Stork, ProBioGen Julian Collins has been appointed as Senior Vice President, Head of People & Organizational Development (P&OD) and a member of the Executive Team. Michiel Stork has taken… Read More

#Business & Investment #News

Pharmaceuticals manufacturing
#ABPI #Appointment #Association of the British Pharmaceutical Industry #New appointment #Pharmaceutical industry #UK

Susan Rienow confirmed as next President of the ABPI 

The ABPI Board has confirmed that Susan Rienow, UK Country President of Pfizer, will be the next President of the Association of the British Pharmaceutical Industry (ABPI).   Rienow was appointed as ABPI Vice-President in September 2022 and will formally take up her role as President in May… Read More

#News

#Appointment #Big pharma #Drug discovery #Life sciences #New appointment #Pharmaceutical industry

February’s key industry appointments

There have been a number of significant appointments in the drug discovery sector over the last month. So who are the latest movers and shakers?  Amy Berrington and Montserrat Garcia-Closas, Institute of Cancer Research: Professors Amy Berrington and Montserrat Garcia-Closas have been appointed as Team Leaders at… Read More

#News

#Appointment #Drug discovery #New appointment

Five key drug discovery appointments

1. Antonin (Tony) de Fougerolles, Etherna  Antonin (Tony) de Fougerolles has joined the Etherna board of directors as an independent member.  He is currently the CEO of Evox Therapeutics. As founding Chief Scientific Officer (CSO) at Moderna Therapeutics, he pioneered modified mRNA.  2. Dr Xavier Jacq, Ubiquigent… Read More

#News

#Biologics / Biotechnology #New appointment #Pharmaceutical industry #Recruitment

Who are drug discovery’s latest movers and shakers?

There have been a number of high-level career moves within the industry in the last couple of weeks. In this update, we provide a round-up of the latest senior appointments and promotions. Nick Maishman, ViroCell Biologics Nick Maishman has joined contract development and manufacturing organisation ViroCell as Chief Operating Officer. Read More

#Business & Investment #News

Lykke Hinsch Gylvin
#Boehringer Ingelheim #New appointment #Pharma #Pharmaceutical industry

Boehringer boosts pharma division with key appointment

Boehringer Ingelheim has appointed Lykke Hinsch Gylvin as Head of Medicine and Chief Medical Officer, effective November 1, 2022. Most recently, Gylvin served as Vice President, Global Medical Franchise Head, Neuroscience at Novartis. She brings more than 20 years of pharmaceutical experience, ranging from early-stage drug development to post-approval lifecycle… Read More

#Business & Investment #News

#New appointment #Recruitment #ValiRx #Women's health

ValiRx appoints interim CSO to drive drug discovery efforts

Life science company ValiRx has appointed Dr Cathy Tralau-Stewart as its interim Chief Scientific Officer (CSO) to help bolster its drug discovery and therapeutic expertise. Dr Tralau-Stewart has over 20 years’ senior academic and industry leadership experience and joins ValiRx from drug discovery company C4X Discovery. At C4X Discovery Dr… Read More

#News